1. Home
  2. PXLW vs RNTX Comparison

PXLW vs RNTX Comparison

Compare PXLW & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PXLW
  • RNTX
  • Stock Information
  • Founded
  • PXLW 1997
  • RNTX 2001
  • Country
  • PXLW United States
  • RNTX United States
  • Employees
  • PXLW N/A
  • RNTX N/A
  • Industry
  • PXLW Semiconductors
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PXLW Technology
  • RNTX Health Care
  • Exchange
  • PXLW Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • PXLW 42.0M
  • RNTX 34.6M
  • IPO Year
  • PXLW 2000
  • RNTX N/A
  • Fundamental
  • Price
  • PXLW $6.13
  • RNTX $1.55
  • Analyst Decision
  • PXLW Strong Buy
  • RNTX Buy
  • Analyst Count
  • PXLW 3
  • RNTX 2
  • Target Price
  • PXLW $13.67
  • RNTX $10.00
  • AVG Volume (30 Days)
  • PXLW 465.8K
  • RNTX 2.5M
  • Earning Date
  • PXLW 11-11-2025
  • RNTX 11-14-2025
  • Dividend Yield
  • PXLW N/A
  • RNTX N/A
  • EPS Growth
  • PXLW N/A
  • RNTX N/A
  • EPS
  • PXLW N/A
  • RNTX N/A
  • Revenue
  • PXLW $33,961,000.00
  • RNTX N/A
  • Revenue This Year
  • PXLW N/A
  • RNTX N/A
  • Revenue Next Year
  • PXLW $23.74
  • RNTX N/A
  • P/E Ratio
  • PXLW N/A
  • RNTX N/A
  • Revenue Growth
  • PXLW N/A
  • RNTX N/A
  • 52 Week Low
  • PXLW $4.67
  • RNTX $1.04
  • 52 Week High
  • PXLW $15.42
  • RNTX $3.99
  • Technical
  • Relative Strength Index (RSI)
  • PXLW 36.39
  • RNTX 57.90
  • Support Level
  • PXLW $6.00
  • RNTX $1.35
  • Resistance Level
  • PXLW $6.47
  • RNTX $1.73
  • Average True Range (ATR)
  • PXLW 0.40
  • RNTX 0.20
  • MACD
  • PXLW -0.12
  • RNTX 0.02
  • Stochastic Oscillator
  • PXLW 9.68
  • RNTX 37.50

About PXLW Pixelworks Inc.

Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: